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Edited by Jesus AvilaAbstract This study set out to search for a link between over-
production of Ab and p70S6 kinase (p70S6K) phosphorylation/
activation. Results showed that levels of p-p70S6K at T421/
S424 and T389 are signiﬁcantly increased in mouse N2a neuro-
blastoma cells carrying human APP with Swedish mutation
(APPswe), and in transgenic APPswe/PS1 (A246E) mice as
compared with respective controls, corresponding to the increase
of tau phosphorylation at S262. This parallel increase in p70S6K
activation and tau phosphorylation could be demonstrated by
treating wild-type N2a cells with Ab25–35. Our results suggest
that the Ab deposition in senile plaques in Alzheimer disease
brains might be a primary event that activates p70S6K and phos-
phorylates tau at S262, resulting in microtubule disruption.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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p70S6 kinase, one of the two isoforms of ribosomal S6 ki-
nase1 (RSK1), is a Ser (S)/Thr (T) – directed kinase that mod-
ulates the phosphorylation of the 40S ribosomal protein S6.
The other isoform of RSK1 is an 85-kDa S6 kinase (p85S6K)
and docked to the nucleus by an additional 23-amino-acid se-
quence at its amino-terminus [1,2]. P70/85 S6 kinases are
formed from the same transcript by two diﬀerent translation
start sites. p70S6 kinase is largely cytoplasmic, and its activa-
tion is crucial to cell growth, cell diﬀerentiation and cell cycle
control. Activation of ribosomal S6 kinase 1 depends on the
its phosphorylation state at eight sites: T229, S371, T389,
S404, S411, S418, T421, and S424 [3,4]. The T229 site of the cat-
alytic domain of p70S6 can be phosphorylated by the activation
of phosphoinositide-dependent protein kinase1 (PDK1), while
the T389 site of the regulatory domain can be phosphorylated
by the mammalian target of rapamycin (mTOR), PDK1 and
never in Mitosis gene related kinase (NEK6/7). Tau protein ki-
nases, such as extracellular signal-regulated protein kinase 1/2
(ERK1/2), c-jun amino-terminal kinase (JNK), phosphoinosi-
tol 3-kinase (PI3K) and p38 mitogen-activated protein kinase*Corresponding author. Fax: +46 8 585 83880.
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doi:10.1016/j.febslet.2007.11.078(p38 MAPK) can phosphorylate S411, S418, T421, S424,
T427 and S429 sites of the autoinhibitory domain [5–8].
Extracellular senile plaques (SPs), which consist of the amy-
loid Ab peptide (Ab), and intracellular neuroﬁbrillary tangles
(NFTs), which are composed of abnormally hyperphosphoryl-
ated tau as paired helical ﬁlaments (PHF-tau), are two main
neuropathological characteristics in Alzheimer disease (AD)
[9,10]. There is evidence that Ab can induce tau hyperphos-
phorylation via many tau kinases, such as PKB/AKT, GSK3,
p38 MAPK, ERK1/2 MAPK and JNK MAPK [11,12]. Our
previous studies demonstrated that the levels of phosphory-
lated (p) p70S6K at T421/S424 and T389 were increased in
AD brains [13], which coincided with the occurrence of PHF-
tau pathology. Phosphorylation and activation of p70S6K were
mediated by the PI3K pathway, complemented by the ERK1/2
MAPK and p38 MAPK pathways [14]. More recently, we
found that p70S6K regulates tau phosphorylation at S262,
S214, T212 sites, as well as tau synthesis [15]. Taken together,
all this evidence implies that p70S6K might associate with tau
hyperphosphorylation, but how p70S6K is activated in the
AD brain and whether p70S6K is involved in Ab-induced tau
phosphorylation remain elusive.
To address these issues, phosphorylation of p70S6K at T421/
S424 and T389, and tau at the S262 site were investigated in
mouse N2a neuroblastoma cells carrying the human APP with
Swedish mutation (APPswe N2a), wild-type N2a cells treated
with Ab25–35, and brain tissues from transgenic mice carrying
both the APPswe and the presenilin (PS) 1 (A246E) mutations.2. Materials and methods
2.1. Materials and reagents
Fresh frozen samples of ventral cortical tissue of 7 transgenic APP-
swe/PS1 (A246E) [16,17] and 7 non-transgenic female mice at 16
months were obtained from a colony at the University of Kuopio.
Polyclonal rabbit antibodies against p70S6K phosphorylated at T389
and total p70S6K were purchased from Cell Signaling Technology
(Beberly, MA, USA). Polyclonal rabbit antibodies against p70S6K
phosphorylated at T421/S424 and tau phosphorylated at the S262 site
were purchased from Biosource Nordic (Stockholm, Sweden). Okadaic
acid (OA), Ab25–35, sodium butyrate and protease-inhibitor cocktail
were from Sigma–Aldrich (Sigma–Aldrich, Stockholm, Sweden).
2.2. Cell culture, treatment, and cell extract preparation
Wild-type N2a cells and APPswe N2a cells were grown in six-well
culture plates (60 mm-diameter) to 70–80% conﬂuence in media
(Dulbeccos modiﬁed Eagles medium, DMEM/Opti-minimum
essential medium, MEM [1:1]; 5% fetal bovine serum (FBS), 1%blished by Elsevier B.V. All rights reserved.
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160 X.-W. Zhou et al. / FEBS Letters 582 (2008) 159–164penicillin/streptomycin [PEST] and 0.2% Fungizone [GIBCO, Invitro-
gen, Stockholm, Sweden]), then the cells were switched to media with
0.5% fetal bovine serum for 24 h. The cells were then treated with 1 lM
sodium butyrate [18] for 12 h with or without further treatment of
100 nM OA for 4 h. For Ab25–35 treatment, the peptide stock solution
at 1 mM was prepared in double-distilled H2O and maintained for 3
days at room temperature to allow polymerization [19]. Wild-type
N2a cells were grown in six-well culture plates to 70–80% conﬂuence,
then switched to media with 0.5% FBS for 24 h, after which cells were
treated with 25 lM Ab25–35 in 0.5% FBS growth medium for 0, 4, 12
or 24 h. At the end of all the treatments, the cells were harvested.
2.3. Extract preparation from cell and mouse tissues, and protein
measurement
After treatment, cells were washed with ice-cold phosphate-buﬀered
saline (PBS), then harvested and suspended in cell lysate buﬀer
containing 2 mM EGTA, 50 mM NaF, 2 mM NaVO4, 0.5 mM
phenylmethylsulfonyl ﬂuoride, 5 mM EDTA, 150 mM NaCl, 50 mM
Tris–HCl (pH 7.4), 1% Triton X-100, protease-inhibitor cocktail
(1:200), sonicated, and ﬁnally kept on ice for 20 min.
Homogenates of tissue from the ventral cortex of transgenic APP-
swe/PS1 (A246E) and control mice were prepared in a buﬀer including
50 mM Tris, pH 7.0, 2.5 mM EDTA, 2.5 mM EGTA, 2 mM Benzam-
idine, 1.0 mM PMSF, 0.1% beta-mercaptoethanol, 20 mM beta-glycer-
ophosphate, 0.1% protease-inhibitor cocktail, 2 mM sodium vanadate,
50 mM NaF, and 2% SDS at 4 C.
Protein concentration was detected with the BCA assay kit from
Pierce (Pierce Chemical, Rockford, IL, USA), and then samples were
stocked at 70 C until used.
2.4. Western blots
After boiling the homogenates of the tissues from mouse or cell ly-
sates for 5 min in a loading buﬀer containing Tris–HCl 62.5 mM, 20%
glycerol, 2% sodium dodecyl sulfate (SDS), 4% beta-mercaptoethanol,
and 0.02% bromophenol, pH 6.8, the samples were loaded and proteins
separated by 10% SDS–PAGE. Proteins were then transferred to nitro-
cellulose membranes. After blocking with 5% (w/v) non-fat milk solu-
tion, the membranes were incubated with respective antibody, then
were detected using horseradish peroxidase-linked anti-rabbit or anti-
mouse IgGs (Amersham Biosciences AB, Uppsala, Sweden) at 1:2000
and the enhanced chemiluminescence kit (Amersham Biosciences AB,
Uppsala, Sweden). Nitrocellulose membranes were stripped by a buﬀer
containing 62.5 mM Tris–HCl, 100 mM beta-mercaptoethanol, 2%
SDS, pH 6.8, and probed with other primary antibodies. Intensities of
positive bands were quantiﬁed with Discovery Series Quantity One 1-D
Analysis Software (Bio-Rad Laboratories Inc., CA, USA).
2.5. Immunocytochemistry
N2a cells were grown on cover-slips in 24-well plates, and treated
with or without 100 nM OA for 4 h. Cover-slips with cells were washed
in PBS, then ﬁxed in 4% paraformaldehyde for 10 min at 4 C and per-
meabilized in Tris-buﬀered saline (TBS) + 0.1% Triton X-100. The
cover-slips were incubated with the primary antibodies against phos-
phorylated p70S6K at T421/S424 sites (1:200) and phosphorylated
tau at the S262 site (1:100) in a moisture chamber at 4 C overnight,
followed by incubation with biotinylated secondary anti-mouse or
anti-rabbit antibodies and the VECTASTAIN ABC-kit. The cells were
visualized by DAB substrate kit for peroxidase (Immunkemi, Ja¨rfa¨lla,
Sweden). After dehydration, the cover-slips with cells were mounted on
slides and dried at room temperature.
2.6. Statistical analysis
Data were analyzed using Students t-test between groups or ANO-
VA followed by least signiﬁcant diﬀerence (LSD) for post hoc test. In
all cases, statistical signiﬁcance was set at level P < 0.05.Fig. 1. p70S6 kinase phosphorylation in APPswe N2a neuroblastoma
cells. Cells were treated with 1 nM sodium butyrate for 12 h, and
samples were separated by Western blots, and detected with antibodies
to phosphorylated (p) p70S6K at T421/S424 and T389 epitoes, and
p-tau at the S262 site. Results showed signiﬁcant increase for p-p70S6K
at T421/S424, and T389 epitopes (Panel A), as well as pS262 (Panel B) in
APPswe N2a cells as compared to wild-type N2a cells. All assays were
repeated at 4–5 times and data were presented with means ± S.D.
*P < 0.05 and **P < 0.01 betweenAPPsweN2a cells wild-typeN2a cells.3. Results
3.1. p70S6 kinase phosphorylation in N2a cells with APP
Swedish mutation
Previous studies have established that p70S6 kinase is able to
phosphorylate tau at the S262 site in vitro [15] and that Abproduction is elevated in APPswe N2a neuroblastoma cells
compared with wild-type N2a cells after treated with sodium
butyrate for 12 h [18]. To investigate the possible eﬀects of
Ab on p70S6K phosphorylation/activation, as well as on tau
phosphorylation at the S262 site, samples from APPswe N2a
and wild-type N2a cells after treatment of 1 nM sodium buty-
rate for 12 h were separated by Western blots, and blotted with
antibodies to phosphorylated (p) p70S6K at T421/S424 or
T389, or an antibody to tau phosphorylation at the pS262 site.
As shown in Fig. 1, antibodies to p-p70S6K showed a signiﬁ-
cant increase at T421/S424 sites (P < 0.01) and the T389 site
(P < 0.05) in APPswe cells as compared with wild-type N2a
cells, while the amount of total p70S6K did not diﬀer (Panel
A of Fig. 1). P-tau at the pS262 site also showed signiﬁcant in-
crease in APPswe N2a cells as compared with wild-type N2a
cells (Panel B of Fig. 1, P < 0.05).
3.2. p70S6 kinase phosphorylation in N2a cells treated with
Ab25–35
Ab25–35 has been shown to activate diﬀerent tau kinases
[12,20]. To further identify the eﬀects of Ab25–35 on
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treated with Ab25–35 (25 lM) and samples were collected at
0, 4, 12 or 24 h. The level of p-p70S6K at T421/S424 was mark-
edly increased at 4 h (P < 0.01), higher than baseline at 12 h
(P < 0.05), but returned to normal at 24 h as compared to con-
trol (0 h) (Fig. 2, panel A). Similarly, the level of p-p70S6K at
the T389 site showed a peak at 4 h, but was restored to normal
already at 12 h (P < 0.05, panel A of Fig. 2A). Levels of tau
phosphorylated at the S262 site showed a similar pattern as
p-p70S6K at T421/S424: a signiﬁcant increase at 4 h
(P < 0.01) and 12 h (P < 0.05) as compared with the baseline,
while levels of tau phosphorylation at PHF-1 sites only showed
signiﬁcant increase at 4 h (P < 0.01) (Fig. 2B).
3.3. p70S6 kinase phosphorylation in the brain of transgenic
mice with APPswe and PS1 mutations
Both Ab40 and Ab42 levels are dramatically elevated in the
brains of transgenic APPswe/PS1 (A246E) female mice after 9
months of age [17]. So we used the transgenic mouse model to
explore the eﬀects of Ab on phosphorylation of p706K at
T421/S424 and T389 epitopes, and tau at the S262 siteP70S6K
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Fig. 2. Eﬀects of Ab25–35 on p70S6 kinase phosphorylation in mouse
wild-type N2a neuroblastoma cells. Wild-type N2a cells were treated
with 25 lM Ab25–35 for 0, 4, 12 or 24 h. Immunoblotts showed
signiﬁcant increase for phosphorylated (p) p70S6K at T421/S424 sites
at 4 and 12 h and the T389 site at 4 h as compared with control (A).
Level of p-tau at the PHF-1 sites and the S262 site showed signiﬁcant
increase at 4 h or 12 h as compared with control (B). Data were
presented with means ± S.D. from 4 to 5 independent experiments.
*P < 0.05, and **P < 0.01, vs. control.in vivo. As compared with non-transgenic littermates (Fig. 3),
there was a signiﬁcant increase of p-p70S6K at both T421/
S424 and T389 sites (P < 0.01, panel A), and p-tau at the the
PHF-1 sites (P < 0.01, panel B) and at the S262 site
(P < 0.05, panel B) in 16-month-old transgenic APPswe/PS1
(A246E) female mice.
3.4. Phosphorylation and localization of p70S6K in N2a cells
treated with okadaic acid
Our previous study demonstrated that selective inhibition of
PP2A by OA can increase phosphorylation of p70S6K at
T421/S424 in metabolically active rat brain slices [15]. To0
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Fig. 3. p70S6 kinase phosphorylation in transgenic APPswe/PS1
(A246E). Homogenates from the ventral cortex of six transgenic
APPswe/PS1 (A246E) (AP) and six non-transgenic mice (NT) were
separated by Western blots and detected by antibodies to phosphor-
ylated (p) p70S6K at T421/S424 and T389 epitopes, and p-tau at the
PHF-1 and S262 sites. Results showed signiﬁcant increase of p-p70S6K
at T421/S424 and T389 (Panel A), and p-tau at the PHF-1 sites or the
S262 site (Panel B). Data were presented with means ± S.D. from 4 to
5 independent experiments; *P < 0.05 vs. NT.
162 X.-W. Zhou et al. / FEBS Letters 582 (2008) 159–164further identify the relationship between p70S6K activation,
tau phosphorylated at the S262 site and Ab, wild-type or APP-
swe N2a cells were treated ﬁrst with 1 nM sodium butyrate
(12 h), then with or without 100 nM OA (4 h), a dose that
selectively inhibits PP2A. Western blots showed a signiﬁcant
increase of p-p70S6K at both T421/S424 and T389 sites in both
wild-type and APPswe OA-treated cell lines (P < 0.01) as com-
pared with non-OA-treated control cells (Panel A of Fig. 4). In
addition, levels of p70S6K phosphorylated at the T421/S424
and T389 sites were higher in control APPswe N2a cells than
in control wild-type N2a cells (Panel A of Fig. 4, P < 0.01).
However, among the OA-treated cells, APPswe cells showed
a signiﬁcant decrease of p-p70S6K at T421/S424 (P < 0.01)
as compared with OA-treated wild-type N2a cells, while the
levels of p-p70S6K at the T389 site showed a signiﬁcant but
smaller diﬀerence (P < 0.05) between OA-treated APPswe
and OA-treated wild-type N2a cells (Panel A of Fig. 4). The
levels of tau phosphorylated at the PHF-1 and S262 sites wereC +OA
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Fig. 4. Eﬀects of okadaic acid (OA) on p70S6 kinase phosphorylation in wil
1 nM sodium butyrate (12 h) and treatment of cells with 100 nM OA (4 h), the
increase for phosphorylated (p) p70S6K at T421/S424 and T389 sites in both
treated control (–) (A). OA-treated APPswe showed signiﬁcant decrease of p-p
treated wild-type N2a cells. Levels of p-p70S6K at T421/S424 and T389 sites
compared with non-OA-treated wild-type N2a cells. Level of p-tau at PHF-1
APPswe and wild-type N2a cell lines as compared to non-OA-treated control
non-OA-treated wild-type control (B). The data were from 4 to 5 independent
treated groups; # Non-OA-treated APPswe vs. Non-OA-treated wild-type.
##P < 0.01; DDP < 0.01. Immunostainings were performed on cover-slips that
for 4 h with antibodies to phosphorylated (p) p70S6K(T421/S424) and p-tau (
S424) and p-tau at the S262 site were observed in the nucleus and cytoplasm o
APPswe control (Con). Scale bar represents 20 lM (C).signiﬁcantly increased in control APPswe N2a cells as com-
pared with control wild-type N2a cells (Fig. 4B, P < 0.05). Sig-
niﬁcant increases of both PHF-1 and pS262 were seen in both
OA-treated APPswe and wild-type N2a cells as compared to
non-OA-treated control (Panel B of Fig. 4). In contrast, a sig-
niﬁcant decrease of pS262 as well as PHF-1 was seen in OA-
treated APPswe as compared to OA-treated wild-type N2a
cells (P < 0.01). Immunocytochemistry conﬁrmed the ﬁndings:
Increased immunoreactivities of p-p70S6K (T421/S424) and p-
tau at the S262 site were observed in the nucleus and process/
cytoplasm of OA-treated APPswe N2a cells as compared to
non-OA-treated control.4. Discussion
Previously, p70S6K has been demonstrated to phosphory-
late tau at a few sites such as S262 but not sites recognizedp-pP70S6K (T421/S424)
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d-type (WT) and APPswe N2a neuroblastoma cells. After treatment of
samples were analyzed by Western blots and results showed signiﬁcant
OA-treated WT and APPswe N2a cell lines as compared with non-OA-
70S6K at T421/S424 with lesser degrees at T389 as compared with OA-
were also signiﬁcantly increased in non-OA-treated APPswe control as
sites or the PS262 site was signiﬁcantly increased in both OA-treated
s, as well as in non-OA-treated APPswe N2a cells control as compared
experiments and presented by means ± S.D. * OA-treated vs. Non-OA-
DOA-treated APPswe vs. OA-treated wild-type. *P < 0.05; **P < 0.01;
ﬁrst treated with 1 nM sodium butyrate for 12 h, then with 100 nM OA
S262). Dramatic increase of the immunoreactivities of p-p70S6K(T421/
f OA-treated APPswe N2a cells treated as compared to non-OA-treated
X.-W. Zhou et al. / FEBS Letters 582 (2008) 159–164 163by PHF-1, the phosphorylation of both sites is increased in
AD brains [13,15]. Moreover, aberrant accumulation of acti-
vated p70S6K (Thr389 or Thr421/Ser424) colocalizes with
PHF-tau pathology in AD brains [13]. The present study ex-
tends these ﬁndings by showing a link between the extracellu-
lar deposition of Ab, activation of p70S6K and increased tau
phosphorylation.
In the APPswe N2a cells that stably overproduce Ab after
treatment of sodium butyrate, levels of p-p70S6K at T421/
S424 and T389 sites were signiﬁcantly increased in APPswe
N2a cells as compared to wild-type N2a cells. The level of p-
tau at the S262 site increased in parallel with the level of
p-p70S6K at T421/S424 sites and the T389 site. This type of
correlation between p70S6K phosphorylation and tau phos-
phorylation at the S262 in relationship to Ab has not been re-
ported before. Several previous studies have demonstrated that
Ab25–35 has a similar toxic eﬀect on cells as Ab1–40/42
[19,21–23]. In the current study, treating wild-type N2a with
25 lM Ab25–35 resulted in a signiﬁcant increase of p-
p70S6K at the T421/S424 sites at 4 h and 12 h, and the T389
site at 4 h. The coinciding increase in the level of p-tau at the
S262 site at 4 h and 12 h similar to the level of p-p70S6K at
T421/S424 sites suggests that p70S6K activity towards tau at
the S262 site is more likely mediated by the signaling events
that regulate T421/S424 phosphorylation than those regulating
the T389 site [5–8]. Tau phosphorylated at the S262 can abol-
ish its ability to promote microtubule assembly [15]. Therefore
it is important to further investigate whether microtubule dis-
ruption seen in AD brain is caused by Ab deposition via aber-
rant activation of the upstream signaling events that activate
p70S6K via phosphorylating T421/S424.
A recent study reported that Ab down-regulates p-p70S6K
on the T389 site after N2a are treated by Ab1-42 for 24 h
[24]. However, this study did not investigate the changes of
p-p70S6K at the T421/S424 site but the changes of p-
p70S6K at the T389 site at an earlier time point such as 4 h
or 12 h. In contrast, the present study showed an increased
phosphorylation of p70S6K at the T389 site after treatment
of 25 lMAb25–35 at 4 h, which appears to return to a normal
level at 12 h. Since Ab25–35 has similar toxic eﬀects as Ab1–42
on the cell [19,21–23], Ab1–42 might also increase the phos-
phorylation of p70S6K at the T389 and tau phosphorylation
at the S262 site after a shorter incubation time such as 4 h.
The transgenic APPswe/PS1 (A246E) mice at the age used
this study show robust Ab deposits in the cerebral cortex
[17]. As predicted, we found increased phosphorylation of
p70S6K at the T421/S424 and T389 sites in transgenic APP-
swe/PS18A246E) mice compared with wild-type mice, which
was accompanied by increased phosphorylation of tau at the
S262 site. Likely the changes were caused by the APPswe gene
mutation, because similar increases were found in N2a cells
carrying the APPswe mutation. However, we cannot fully rule
out the possibility that the PS1 gene mutation has addition ef-
fects to APPswe gene mutation in causing p70S6K activation
and tau phosphorylation at the S262 site.
PP2A activity is reduced in AD brains [25,26], and selective
inhibition of PP2A by OA can up-regulate p70S6K phosphor-
ylation at the T421/S424 and T389 sites [27,28]. It has been
also demonstrated that the S262 site of tau can be phosphory-
lated by several kinases, such as calcium/calmodulin-depen-
dent protein kinase II (CamKII), microtubule-aﬃnity
regulating kinase (MARK), protein kinase A, as well asp70S6K [15,29]. This suggests that an antibody against tau
phosphorylated at the S262 site can serve as a marker for
p70S6K activity, although it is not speciﬁc. Consistent with
the data from metabolically active rat brain slices, 100 nM
OA that selectively inhibits PP2A up-regulates p70S6K at
the T421/S424 sites and the T389 site in both wild-type and
APPswe N2a cells. Although the baseline levels of p-p70S6K
at the T421/S424 and T389 sites were signiﬁcantly increased
in APPswe as compared to wild-type N2a cells, OA treatment
resulted in lower levels of phosphorylated p70S6K at the T421/
S424 site in APPswe N2a cells than in wild-type N2a cells. Our
recent data showed that Ab overproduction can reduce PP2A
activity via up-regulation of PP2A phosphorylation at the
Y307 site (not published). Taken together, it suggested that
in the brains of familial AD with Swedish mutations a contra-
dictory mechanism might exist rather than an expected syner-
gic action of selective PP2A inhibition and Ab overproduction
on p70S6K activation and tau phosphorylation at the S262
site. Similar changing tendency of tau phosphorylation at
PHF-1 sites seen in the above discussed conditions to S262
might be caused simply by inhibited PP2A activity, and/or
other tau kinases such as non-ERK1/2 but rapamycin-sensitive
since p70S6K is not able to phosphorylate tau at PHF-1 sites
in vitro [15].
In summary, extracellular deposition of Ab in AD brains
might be a primary event that activates p70S6K and phosphor-
ylates tau at the S262 site, resulting in microtubule disruption.
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